Dec 16, 20241 min readThe market for ‘gene silencing’ therapies is set to explode Dan Williams discusses the reasons behind this in FirstWord Pharma. Read his analysis here.
Dan Williams discusses SynaptixBio’s history, status, and aspirations in a major interview for leading US biotech podcast RAREcast
Amy Sheridan-Hill, co-founder of the H-ABC Foundation, and Dan Williams in major Mirror story about hopes for new drug
SynaptixBio’s collaboration with leading global drug researcher Evotec featured in European Biotechnology Magazine
Comments